Adding Bempedoic Acid to Statin Therapy Reduces LDL Cholesterol
Genetic variants mimicking effect of ATP citrate lyase inhibitors, statins lower LDL-C in same way.
Hyperlipoproteinemias
Does Age Impact Alirocumab Efficacy in Patients With HeFH?
Alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, was found to be both safe and effective in reducing low-density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH) across different age groups, according to a post-hoc analysis.
Praluent Soon to Be Available at Reduced Price
Regeneron and Sanofi announced that both doses of Praluent (alirocumab) will be made available at a new US list price—60% lower than the original—in early March.
Fish Oil Dietary Supplement Use Examined Among Cardiac Patients
A recently published study found that the majority of cardiac patients utilizing fish oil dietary supplements did so without the recommendation of a healthcare professional and without proper medical supervision.
All Repatha Devices Launched at Reduced List Price
Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an on-body infusor with prefilled cartridge.
Cost-Effectiveness of Alirocumab vs Ezetimibe Added to Statin Examined
Price of alirocumab would have to decrease from original cost of 14,560 to 1,974 to be cost-effective
Update on Medical Overuse Highlights Practices That May Harm More Than Help
The review, which was the fifth annual update discussing medical care overuse, aimed to identify and highlight research articles and literature published in 2017 related to medical overuse in adult patients.
AHA: Statin Benefits Outweigh Risks With Low Risk of Adverse Effects
The data showed a <0.1% risk of statin-induced muscle injury, including rhabdomyolysis, and a ~0.001% risk of serious hepatotoxicity. Statin-induced newly diagnosed diabetes mellitus was a ~0.2% risk per year of treatment, depending on baseline risk in the patients studied.
Antisense Drug Can Safely and Effectively Reduce Elevated Lipoprotein(a)
Researchers aimed to find the optimal dose and regimen of AKCEA-APO(a)-LRX injected subcutaneously for further clinical development.
Can Omega-3 Help Reduce MACE in High Risk Patients With Hypertriglyceridemia?
In high-risk patients with mild hypertriglyceridemia, omega-3 fatty acids improved triglyceride levels and reduced major adverse cardiovascular events, according to a new meta-analysis.
